Transplantation tolerance: Clinical potential of regulatory T cells

Self/Nonself - Immune Recognition and Signaling

Volumn 2, Issue 1, 2011, Pages 26-34

  Muller, Yannick D ^a   Seebach, Jörg D ^a   Bühler, Leo H ^a   Pascual, Manuel ^b   Golshayan, Dela ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cell therapy; Regulatory t cells; Tolerance; Transplantation

Indexed keywords

CD3 ANTIBODY; CD39 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GALECTIN 1; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HLA ANTIGEN CLASS 2; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 35; INTERLEUKIN 7 RECEPTOR ALPHA; LATENCY ASSOCIATED PEPTIDE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT REJECTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELL THERAPY; DOWN REGULATION; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LIVER TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T CELL DEPLETION; TRANSPLANTATION TOLERANCE;

EID: 79960377320     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.2.1.15422     Document Type: Review

References (143)

1. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172:603-6.
2. Sayegh MH, Carpenter CB. Transplantation 50 years later-progress, challenges and promises. N Engl J Med 2004; 351:2761-6.
3. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346:580-90.
4. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378-83.
5. Hernandez-Fuentes MP, Lechler RI. Chronic graft loss. Immunological and non-immunological factors. Contrib Nephrol 2005; 146:54-64.
6. Ashton-Chess J, Giral M, Brouard S, Soulillou JP. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation 2007; 84:1215-9.
7. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism and graft acceptance. Lancet 1992; 339:1579-82.
8. Strober S, Benike C, Krishnaswamy S, Engleman EG, Grumet FC. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation 2000; 69:1549-54.
9. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, Chin T, Kusaka S, Geissler F, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106:145-55.
10. Anderson DBR, Lampkin GH, Medawar P. Use of skin grafting to distinguish between monzygotic and dizygotic twins in cattle. Heredity 1951; 5:379.
11. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14:417-24.
12. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307:168-70.
13. Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6:464-9.
14. Buhler LH, Spitzer TR, Sykes M, Sachs DH, Delmonico FL, Tolkoff-Rubin N, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74:1405-9.
15. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358:362-8.
16. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-61.
17. Fuchimoto Y, Huang CA, Yamada K, Shimizu A, Kitamura H, Colvin RB, et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest 2000; 105:1779-89.
18. Kawai T, Sogawa H, Boskovic S, Abrahamian G, Smith RN, Wee SL, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4:1391-8.
19. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003; 3:147-58.
20. Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian UH. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol 2006; 7:1092-100.
21. Gershon RK. A disquisition on suppressor T cells. Transplant Rev 1975; 26:170-85.
22. Hall BM, Jelbart ME, Dorsch SE. Suppressor T cells in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Transplantation 1984; 37:595-600.
23. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985; 161:72-87.
24. + T cell subset that inhibits this autoimmune potential. J Exp Med 1993; 177:627-36.
25. + T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med 1990; 172:1701-8.
26. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
27. + regulatory T cells. Nat Immunol 2003; 4:330-6.
28. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27:68-73.
29. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27:18-20.
30. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20-1.
31. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
32. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 2005; 102:5126-31.
33. - T cells. J Clin Invest 2003; 112:1437-43.
34. + Treg cells. J Exp Med 2006; 203:1701-11.
35. high cell population in solid organ transplant recipients. J Exp Med 2007; 204:1533-41.
36. + T cells expressing the FoxP3 transcription factor. Immunity 30:899-911.
37. Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, Poschl J, et al. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 2006; 108:3371-8.
38. + regulatory T cells in human thymus and periphery. Immunity 2008; 28:870-80.
39. + regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490-500.
40. + precursors in a thymus-independent process. J Immunol 2004; 172:923-8.
41. + regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004; 172:6003-10.
42. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212:28-50.
43. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2002; 196:255-60.
44. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-42.
45. + regulatory T cells by TGFbeta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86.
46. - T cells through Foxp3 induction and downregulation of Smad7. J Immunol 2004; 172:5149-53.
47. + regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004; 101:4572-7.
48. Weiner HL. Induction and mechanism of action of transforming growth factorbeta-secreting Th3 regulatory cells. Immunol Rev 2001; 182:207-14.
49. Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Dong J, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37:2378-89.
50. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010; 463:808-12.
51. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009; 30:80-91.
52. Selvaraj RK, Geiger TL. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGFbeta. J Immunol 2007; 178:7667-77.
53. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T (H) 17 lineage. Nature 2006; 441:231-4.
54. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24:179-89.
55. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8.
56. +FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110:2983-90.
57. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192:295-302.
58. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168:1080-6.
59. Nakamura K, Kitani A, Strober W. Cell contact dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194:629-44.
60. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16:311-23.
61. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity 2004; 21:503-13.
62. + T cells. Blood 2007; 109:2058-65.
63. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110:1225-32.
64. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21:589-601.
65. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11:1093-101.
66. Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009; 21:612-8.
67. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting Interleukin 2 production. J Exp Med 1998; 188:287-96.
68. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6:1142-51.
69. + regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005; 6:1152-9.
70. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002; 196:851-7.
71. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665-74.
72. Stockinger B, Kassiotis G, Bourgeois C. Homeostasis and T cell regulation. Curr Opin Immunol 2004; 16:775-9.
73. + T cells for IL-2 and exploit it for the induction of IL-10 production. Int Immunol 2005; 17:279-88.
74. + Treg cells fit. Nat Immunol 2005; 6:1071-2.
75. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164:183-90.
76. Szymczak-Workman AL, Workman CJ, Vignali DA. Cutting edge: regulatory T cells do not require stimulation through their TCR to suppress. J Immunol 2009; 182:5188-92.
77. + regulatory T cells downregulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000; 30:1538-43.
78. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7:83-92.
79. + T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003; 197:111-9.
80. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001; 2:1126-32.
81. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-74.
82. Li J, Meinhardt A, Roehrich ME, Golshayan D, Dudler J, Pagnotta M, et al. Indoleamine-2,3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Heart Circ Physiol 2007; 293:3415-23.
83. Waldmann H, Adams E, Fairchild P, Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol Rev 2006; 212:301-13.
84. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106:263-6.
85. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation: Friend or foe? Immunity 2001; 14:357-68.
86. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nature Rev Immunol 2007; 7:610-21.
87. + regulatory T cells inhibit natural killer cell functions in a transforming growth factorbeta-dependent manner. J Exp Med 2005; 202:1075-85.
88. high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245-53.
89. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007; l:145-59.
90. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004; 104:895-903.
91. + regulatory T cells. Blood 2006; 107:1018-23.
92. + regulatory T cells promote experimental transplantation tolerance. Blood 2007; 109:827-35.
93. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199:1455-65.
94. Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion and Treg cryopreservation. PLoS One 2008; 3:3161.
95. Allan SE, Song-Zhao GX, Abraham T, McMurchy AN, Levings MK. Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol 2008; 38:3282-9.
96. + regulatory T cells and for expansion of these cells. J Immunol 2007; 178:2018-27.
97. Gao W, Thompson L, Zhou Q, Putheti P, Fahmy TM. Strom TB, et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle 2009; 8:1444-50.
98. + regulatory T cells. Proc Natl Acad Sci USA 2008; 105:18460-5.
99. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance and function of induced regulatory T cells. J Exp Med 2009; 206:3015-29.
100. +Tregs. Blood 2007; 110:2501-10.
101. Mariat C, Degauque N, Strom TB. TIM-1: a new player in transplant immunity. Transplantation 2009; 87:84-6.
102. +cells. J Exp Med 2008; 205:565-74.
103. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008; 7:458-62.
104. hi Cells. Immunity 2008; 29:758-70.
105. Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH, et al. Indoleamine-2,3-dioxygenaseexpressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009; 114:555-63.
106. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009; 183:2475-83.
107. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 2010; 11:846-53.
108. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using co-stimulatory blockade. Curr Opin Immunol 2002; 14:592-600.
109. Ndhlovu LC, Takeda I, Sugamura K, Ishii N. Expanding role of T-cell costimulators in regulatory T-cell function: recent advances in accessory molecules expressed on both regulatory and nonregulatory T cells. Crit Rev Immunol 2004; 24:251-66.
110. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8:2086-96.
111. +regulatory T-cells. J Am Soc Nephrol 2006; 17:2844-53.
112. + regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008; 8:793-802.
113. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18:1007-18.
114. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L. TGFbeta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9:1202-8.
115. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med 2008; 14:528-35.
116. Morelli AE. The immune regulatory effect of apoptotic cells and exosomes on dendritic cells: its impact on transplantation. Am J Transplant 2006; 6:254-61.
117. Wells AD, Li XC, Li Y, Walsh M, Zeng XX, Wu Z, et al. Requirement for T cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5:1039-46.
118. + regulatory T cells. Blood 2005; 105:4743-8.
119. Muller YD, Mai G, Morel P, Serre-Beinier V, Gonelle-Gispert C, Yung GP, et al. Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation. PLoS One 2010; 5:10352.
120. Zheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T-cells to create transplantation tolerance. Immunity 2003; 19:503-14.
121. + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108:1571-9.
122. Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, et al. In vivo expansion of Treg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009; 206:751-60.
123. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004; 99:1467-77.
124. Sayegh M, Zheng X, Magee C, Hancock W, Turka L. Donor antigen is necessary for the prevention of chronic rejection in CTLA-4-Ig-treated murine cardiac allografts. Transplantation 1997; 64:1646-50.
125. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99:3493-9.
126. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9:1144-50.
127. - T regulatory cells. Clin Immunol 2009; 133:22-6.
128. Jiang S, Tsang J, Tam P. Regulatory T cell immunotherapy for transplantation tolerance: step into clinic. Int Immunopharmacol 2010; 10:1486-90.
129. Gökmen MR, Lombardi G, Lechler RI. The importance of the indirect pathway of allorecognition in clinical transplantation. Curr Opin Immunol 2008; 20:568-74.
130. + regulatory T lymphocytes. Nat Med 2008; 14:88-92.
131. + regulatory T cell treatment for the induction of donor-specific transplantation tolerance. Int Immunopharmacol 2006; 6:1879-82.
132. + Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 2008; 118:3619-28.
133. Wise MP, Bemelman F, Cobbold SP, Waldmann H. Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol 1998; 161:5813-6.
134. Pilat N, Baranyi U, Klaus C, Jaeckel E, Mpofu N, Wrba F, et al. Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant 2010; 10:751-62.
135. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29:44-56.
136. Chen L, Ahmed E, Wang T, Wang Y, Ochando J, Chong AS, et al. TLR signals promote IL6/IL-17-dependent transplant rejection. J Immunol 2009; 182:6217-25.
137. Ahmed EB, Daniels M, Alegre ML, Chong AS. Bacterial infections, alloimmunity and transplantation tolerance. Transplant Rev 2011; 25:27-35.
138. Hanidziar D, Koulmanda M. Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance. Curr Opin Organ Transplant 2010; 15:411-5.
139. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10:1000-7.
140. Muller YD, Golshayan D, Ehirchiou D, Wekerle T, Seebach JD, Bühler LH. T regulatory cells in xenotransplantation. Xenotransplantation 2009; 16:121-8.
141. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7:610-21.
142. Dilek N, van Rompaey N, Le Moine A, Vanhove B. Myeloid-derived suppressor cells in transplantation. Curr Opin Organ Transplant 2010; 15:765-8.
143. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al. Immune Tolerance Network ST507 Study Group. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120:1836-47.